Cell-free DNA as a diagnostic marker for cancer: current insights
- PMID: 27822059
- PMCID: PMC5087772
- DOI: 10.2147/OTT.S100901
Cell-free DNA as a diagnostic marker for cancer: current insights
Abstract
The increasing knowledge of the molecular pathogenesis of cancer and the rapid development of new molecular techniques are promoting the study of early molecular alterations involved in cancer development in body fluids. Specific genetic and epigenetic alterations could be found in plasma, serum, and urine cell-free DNA (cfDNA) and could potentially be used as diagnostic biomarkers for several types of cancers. This review focuses on the role of cfDNA in diagnosis: a PubMed search was performed by selecting papers according to journal impact factor and robustness of statistical analysis. A comprehensive evaluation of "liquid biopsy", including cfDNA analysis, will be one of the critical challenges to better understand the early mechanisms of cancer development.
Keywords: cancer; cell-free DNA; diagnosis; liquid biopsy.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Similar articles
-
Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer.Cancers (Basel). 2019 Jun 11;11(6):805. doi: 10.3390/cancers11060805. Cancers (Basel). 2019. PMID: 31212602 Free PMC article. Review.
-
Finding new cancer epigenetic and genetic biomarkers from cell-free DNA by combining SALP-seq and machine learning.Comput Struct Biotechnol J. 2020 Jul 7;18:1891-1903. doi: 10.1016/j.csbj.2020.06.042. eCollection 2020. Comput Struct Biotechnol J. 2020. PMID: 32774784 Free PMC article.
-
Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy.Genes (Basel). 2019 Jan 9;10(1):32. doi: 10.3390/genes10010032. Genes (Basel). 2019. PMID: 30634483 Free PMC article. Review.
-
Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.Crit Rev Oncol Hematol. 2019 Sep;141:36-42. doi: 10.1016/j.critrevonc.2019.06.005. Epub 2019 Jun 7. Crit Rev Oncol Hematol. 2019. PMID: 31212145 Review.
-
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.Transl Lung Cancer Res. 2016 Oct;5(5):511-516. doi: 10.21037/tlcr.2016.10.14. Transl Lung Cancer Res. 2016. PMID: 27826532 Free PMC article. Review.
Cited by
-
Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.Int J Mol Sci. 2018 Oct 26;19(11):3356. doi: 10.3390/ijms19113356. Int J Mol Sci. 2018. PMID: 30373199 Free PMC article.
-
Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis.Cancer Manag Res. 2018 Aug 30;10:3125-3139. doi: 10.2147/CMAR.S174237. eCollection 2018. Cancer Manag Res. 2018. PMID: 30214305 Free PMC article.
-
Urinary Markers for Bladder Cancer Diagnosis and Monitoring.Front Cell Dev Biol. 2022 May 2;10:892067. doi: 10.3389/fcell.2022.892067. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35586337 Free PMC article. Review.
-
Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions.Noncoding RNA. 2022 Aug 10;8(4):60. doi: 10.3390/ncrna8040060. Noncoding RNA. 2022. PMID: 36005828 Free PMC article. Review.
-
Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening.Iran Biomed J. 2018 Sep;22(5):331-7. doi: 10.29252/ibj.22.5.331. Epub 2018 Feb 24. Iran Biomed J. 2018. PMID: 29475366 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. - PubMed
-
- Chan AK, Chiu RW, Lo YM, Clinical Sciences Reviews Committee of the Association of Clinical Biochemists Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem. 2003;40(Pt 2):122–130. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources